Document is current
Any future updates will be listed below
-
Authors
Salazar de Pablo, Gonzalo https://orcid.org/0000-0002-6992-0767
Iniesta, Raquel
Bellato, Alessio https://orcid.org/0000-0001-5330-6773
Caye, Arthur https://orcid.org/0000-0002-5341-7147
Dobrosavljevic, Maja
Parlatini, Valeria https://orcid.org/0000-0002-4754-2494
Garcia-Argibay, Miguel https://orcid.org/0000-0002-4811-2330
Li, Lin https://orcid.org/0000-0002-7946-4574
Cabras, Anna
Haider Ali, Mian https://orcid.org/0009-0002-5003-9512
Archer, Lucinda
Meehan, Alan J. https://orcid.org/0000-0001-7169-997X
Suleiman, Halima
Solmi, Marco https://orcid.org/0000-0003-4877-7233
Fusar-Poli, Paolo https://orcid.org/0000-0003-3582-6788
Chang, Zheng
Faraone, Stephen V.
Larsson, Henrik https://orcid.org/0000-0002-6851-3297
Cortese, Samuele https://orcid.org/0000-0001-5877-8075
- License Information
-
More Information
Article History
Received: 28 September 2023
Revised: 30 April 2024
Accepted: 9 May 2024
First Online: 23 May 2024
Competing interests
: Dr. Salazar de Pablo has received honoraria from Janssen Cilag, Lundbeck and Angelini. Dr Archer is supported by funding from the NIHR Birmingham Biomedical Research Centre at the University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham. Dr. Solmi has received honoraria/has been a consultant for Abbvie, Angelini, Lundbeck, Otsuka. Prof. Fusar-Poli has received grant support from Lundbeck and honoraria fees from Angelini, Menarini, and Lundbeck. In the past year, Dr. Faraone received income, potential income, travel expenses continuing education support and/or research support from Aardvark, Aardwolf, AIMH, Tris, Otsuka, Ironshore, KemPharm/Corium, Akili, Supernus, Atentiv, Noven, Sky Therapeutics, Axsome and Genomind. With his institution, he has US patent US20130217707 A1 for the use of sodium-hydrogen exchange inhibitors in the treatment of ADHD. He also receives royalties from books published by Guilford Press: Straight Talk about Your Child’s Mental Health, Oxford University Press: Schizophrenia: The Facts and Elsevier: ADHD: Non-Pharmacologic Interventions. He is Program Director of and . Prof Larsson reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals and Evolan Pharma AB; all outside the submitted work. Henrik Larsson is editor-in-chief of JCPP Advances. Prof. Cortese has declared reimbursement for travel and accommodation expenses from the Association for Child and Adolescent Central Health (ACAMH) in relation to lectures delivered for ACAMH, the Canadian AADHD Alliance Resource, the British Association of Psychopharmacology, and from Healthcare Convention for educational activity on ADHD.
